Given the lack of information regarding expression of MCT1 and MCT4 in melanoma tumor tissues and the availability of highly specific small molecule MCT inhibitors, several of which are in early clinical development (e.g. CRUKD/12/004; a phase I study of AZD3965, an MCT1 inhibitor, in advanced MCT1-expressing cancers), we became interested in studying the expression of MCT1 and MCT4 in the nevus>melanoma TMA. The gene discussed is SLC16A1; the disease is cancer.